SCHEMBL4132392

SCHEMBL4132392

COc1ncc(NC(=O)Cc2ccccc2)c(Cl)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 1/20 0.50
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 1/20 0.46
NOD2 Q9HC29 1/20 0.46
CCNE1 P24864 2/20 0.46
CDK2 P24941 2/20 0.46
CDK5 Q00535 2/20 0.46
GALR3 O60755 1/20 0.46
HTT P42858 1/20 0.46
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPK10 P53779 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132347 0.80 CCNE1 (0.51) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL4144040 0.80 LMNA (0.54) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL4132365 0.80 CCNE1 (0.49) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL4006345 0.72 SMN1; SMN2 (0.54) MEN1KMT2ARAB9ASMN1; SMN2ALDH1A1
SCHEMBL6169172 0.71 MEN1 (0.83) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL13530881 0.71 ALDH1A1 (0.48) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL23331269 0.70 MEN1 (0.64) MEN1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL20596981 0.70 L3MBTL1 (0.64) MEN1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL30116211 0.70 L3MBTL1 (0.64) MEN1KMT2APOLBRAB9ASMN1; SMN2
SCHEMBL24978697 0.70 CSNK1D (0.49) MEN1KMT2APOLBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005560-A1 PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS AJINOMOTO CO. INC (JP) 2009-01-01 US disclosed
EP-2009003-A1 Production method of diaminopyrimidine compounds Ajinomoto Co., Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005560-A1 PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS DPYD, DHPS, UMPS MEN1 2530/4885KMT2A 1803/4885POLB 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.